Cisplatin is used to effectively treat many types of cancer, but also causes numerous side effects and toxicities. Cisplatin dosing must often be limited because of side effects of this treatment, including irreversible hearing loss and other ototoxicities. Cisplatin also causes nephrotoxicity and neurotoxicity. Transplatin, the steroisomer of cisplatin, has long been regarded as clinically inactive against tumors and relatively non-toxic compared to cisplatin. This licensing opportunity is a new use for transplatin based on the finding that transplatin can act as a protective/therapeutic agent against toxicities related to cisplatin and other platinum-containing anti-tumor compounds without reducing the anti-tumor efficacy of these platinum-based treatments. Transplatin also has other protective effects relating to aminoglycosides, noise, and radiation, and may be effective in treating pain.

File Number: 2.129.131 

Web site: http://www.siumed.edu/adrfa/techavailable.html

Disease: Cancer

Other Information: Proof of concept data shows that transplatin protects from ototoxicity and nephrotoxicity induced by cisplatin. Additional studies for noise and aminoglycosides are planned.